These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

81 related items for PubMed ID: 26034126

  • 1. SLFN11: Achilles' Heel or Troublemaker.
    Kovar H.
    Clin Cancer Res; 2015 Sep 15; 21(18):4033-4. PubMed ID: 26034126
    [Abstract] [Full Text] [Related]

  • 2. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
    Tang SW, Bilke S, Cao L, Murai J, Sousa FG, Yamade M, Rajapakse V, Varma S, Helman LJ, Khan J, Meltzer PS, Pommier Y.
    Clin Cancer Res; 2015 Sep 15; 21(18):4184-93. PubMed ID: 25779942
    [Abstract] [Full Text] [Related]

  • 3. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T, Giorgi C, Schmidt O, Calzada-Wack J, Neff F, Buch T, Niggli FK, Schäfer BW, Burdach S, Richter GH.
    Oncotarget; 2016 Jan 12; 7(2):1451-63. PubMed ID: 26623725
    [Abstract] [Full Text] [Related]

  • 4. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
    Kovar H.
    Expert Opin Ther Targets; 2014 Nov 12; 18(11):1315-28. PubMed ID: 25162919
    [Abstract] [Full Text] [Related]

  • 5. Detection of EWS/FLI-1 fusion in non-Ewing soft tissue tumors.
    Trancău IO, Huică R, Surcel M, Munteanu A, Ursaciuc C.
    J Med Life; 2015 Nov 12; 8(1):85-9. PubMed ID: 25914746
    [Abstract] [Full Text] [Related]

  • 6. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
    Cidre-Aranaz F, Grünewald TG, Surdez D, García-García L, Carlos Lázaro J, Kirchner T, González-González L, Sastre A, García-Miguel P, López-Pérez SE, Monzón S, Delattre O, Alonso J.
    Oncogene; 2017 Feb 09; 36(6):766-776. PubMed ID: 27375017
    [Abstract] [Full Text] [Related]

  • 7. PRAS40 is a functionally critical target for EWS repression in Ewing sarcoma.
    Huang L, Nakai Y, Kuwahara I, Matsumoto K.
    Cancer Res; 2012 Mar 01; 72(5):1260-9. PubMed ID: 22241085
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
    Theisen ER, Pishas KI, Saund RS, Lessnick SL.
    Oncotarget; 2016 Apr 05; 7(14):17616-30. PubMed ID: 26848860
    [Abstract] [Full Text] [Related]

  • 9. Ewing's Sarcoma.
    Riggi N, Suvà ML, Stamenkovic I.
    N Engl J Med; 2021 Jan 14; 384(2):154-164. PubMed ID: 33497548
    [No Abstract] [Full Text] [Related]

  • 10. Cruel fusion: What a young man's death means for childhood cancer.
    Ledford H.
    Nature; 2017 Mar 28; 543(7647):608-611. PubMed ID: 28358102
    [No Abstract] [Full Text] [Related]

  • 11. The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease.
    Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Grünewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, Lawlor E, Lessnick S, Ludwig J, Meltzer P, Metzler M, Mora J, Moriggl R, Nakamura T, Papamarkou T, Radic Sarikas B, Rédini F, Richter GH, Rossig C, Schadler K, Schäfer BW, Scotlandi K, Sheffield NC, Shelat A, Snaar-Jagalska E, Sorensen P, Stegmaier K, Stewart E, Sweet-Cordero A, Szuhai K, Tirado OM, Tirode F, Toretsky J, Tsafou K, Üren A, Zinovyev A, Delattre O.
    Oncotarget; 2016 Feb 23; 7(8):8613-24. PubMed ID: 26802024
    [Abstract] [Full Text] [Related]

  • 12. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
    Giorgi C, Boro A, Rechfeld F, Lopez-Garcia LA, Gierisch ME, Schäfer BW, Niggli FK.
    Oncotarget; 2015 Oct 06; 6(30):28895-910. PubMed ID: 26336820
    [Abstract] [Full Text] [Related]

  • 13. Development of Mithramycin Analogues with Increased Selectivity toward ETS Transcription Factor Expressing Cancers.
    Mitra P, Eckenrode JM, Mandal A, Jha AK, Salem SM, Leggas M, Rohr J.
    J Med Chem; 2018 Sep 13; 61(17):8001-8016. PubMed ID: 30114371
    [Abstract] [Full Text] [Related]

  • 14. Plasma hydrogenated cationic detonation nanodiamonds efficiently deliver to human cells in culture functional siRNA targeting the Ewing sarcoma junction oncogene.
    Bertrand JR, Pioche-Durieu C, Ayala J, Petit T, Girard HA, Malvy CP, Le Cam E, Treussart F, Arnault JC.
    Biomaterials; 2015 Mar 13; 45():93-8. PubMed ID: 25662499
    [Abstract] [Full Text] [Related]

  • 15. C/EBPβ-1 promotes transformation and chemoresistance in Ewing sarcoma cells.
    Gardiner JD, Abegglen LM, Huang X, Carter BE, Schackmann EA, Stucki M, Paxton CN, Lor Randall R, Amatruda JF, Putnam AR, Kovar H, Lessnick SL, Schiffman JD.
    Oncotarget; 2017 Apr 18; 8(16):26013-26026. PubMed ID: 28148901
    [Abstract] [Full Text] [Related]

  • 16. Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma.
    Tosso PN, Kong Y, Scher L, Cummins R, Schneider J, Rahim S, Holman KT, Toretsky J, Wang K, Üren A, Brown ML.
    J Med Chem; 2014 Dec 26; 57(24):10290-303. PubMed ID: 25432018
    [Abstract] [Full Text] [Related]

  • 17. Targeting the EWS-FLI1 transcription factor in Ewing sarcoma.
    Tancredi R, Zambelli A, DaPrada GA, Fregoni V, Pavesi L, Riccardi A, Burdach S, Grohar PJ, D'Incalci M.
    Cancer Chemother Pharmacol; 2015 Jun 26; 75(6):1317-20. PubMed ID: 25809543
    [Abstract] [Full Text] [Related]

  • 18. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
    Tirado OM, Mateo-Lozano S, Villar J, Dettin LE, Llort A, Gallego S, Ban J, Kovar H, Notario V.
    Cancer Res; 2006 Oct 15; 66(20):9937-47. PubMed ID: 17047056
    [Abstract] [Full Text] [Related]

  • 19. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.
    Prieur A, Tirode F, Cohen P, Delattre O.
    Mol Cell Biol; 2004 Aug 15; 24(16):7275-83. PubMed ID: 15282325
    [Abstract] [Full Text] [Related]

  • 20. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN, Tang N, Fleming JT, Ma Y, Guo Y, Borinstein SC, Chiang C, Wang J.
    Oncotarget; 2016 Jul 12; 7(28):43504-43517. PubMed ID: 27259270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.